Loading stock data…
ZURA
$5.21+0.13 (+2.56%)
Market ClosedLast close May 1
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zura Bio Limited in the Healthcare sector is trading at $5.21. The stock is currently 30% below its 52-week high of $7.44, remaining 23.2% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why ZURA maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.21
Potential Upside
5%
Whystock Fair Value$5.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$15.50+197.5%
Range$11.00 – $26.00
Fundamentals
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody enginee...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$539.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-67.61%
Volume
Today's trading volume
407,948
Recent News
One Zura Bio Insider Raised Their Stake In The Previous Year
Viewing insider transactions for Zura Bio Limited's ( NASDAQ:ZURA ) over the last year, we see that insiders were net...
UniFirst, Elastic NV, and More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.